Hollow Mesoporous Silica@Zeolitic Imidazolate Framework Capsules and Their Applications for Gentamicin Delivery.

Xiaoxiang Xu,Xia Wu,Weijia Kong,Heyin Chen,Haoquan Zheng,Kai Xu,Zuhong He,Le Xie,Yu Sun,Jing Qi,Shengyu Zou,Haitao Yuan,Sen Chen

doi:10.1155/2018/2160854

Abstract

We have synthesized hollow mesoporous silica (HMS) at a zeolitic imidazolate framework (ZIF) capsule that can be used as a drug delivery system for gentamicin (GM). The GM is first loaded into HMS. Then, the outer surface of the GM/HMS is coated with uniformed ZIF nanoparticles (denoted as GM/HMS@ZIF). The GM/HMS@ZIF has been successfully prepared and acts as a capsule for GM. The GM/HMS@ZIF shows a good biocompatibility and a good cellular uptake in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells. The GM is released slowly within 10 h under acidic conditions, which is used to simulate the pH of the endosome and lysosome compartments. The in vivo assay shows that the signal from fluorescein isothiocyanate (FITC) can be observed after 15 days, when the mice were injected with FITC/HMS@ZIF. This opens new opportunities to construct a delivery system for GM via one controlled low dose and sustained release for the therapy of Ménière's disease.

Highlights

Ménière’s disease is a common inner ear disorder [1]
We demonstrate the sustained release of GM from the GM/hollow mesoporous silica (HMS)@zeolitic imidazolate framework (ZIF) capsule by in vitro and in vivo assays
The powder X-ray diffraction (PXRD) patterns of solid MS, HMS, and GM/HMS showed a broad peak at 20°, which was attributed to the amorphous framework of the silica (Figures 3(a) and 3(b))

Summary

Introduction

Ménière’s disease is a common inner ear disorder [1]. The clinical observation of Ménière’s disease includes episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness, which negatively impacts the patient’s life both physically and psychosocially. The gentamicin (GM) administration has been widely used for the treatment of Ménière’s disease and has demonstrated to be effective in clinical applications. To avoid the systemic effect of aminoglycoside, Schuknecht developed a technique to deliver streptomycin intratympanically, which could control vertigo admirably [2]. Intratympanic injection proves to be efficient, the high dose of the gentamicin in the local area of ears causes ototoxicity [3]. Controllable delivery systems for GM via sustained release have attracted many scientists’ attentions. This kind of delivery system could deliver a precise and consistent amount of medicine to the round window due to continuous release of low-dose drug [14]. It is still challenging to construct a designable drug delivery system that can continuously release gentamicin and allow the control of the administration of the drug

Methods

Results

Conclusion